H.C. Wainwright

H.C. Wainwright has slashed its price target on Relpsa Inc (NASDAQ: RLYP) shares to $32 from $36. However, the brokerage maintained the rating of Buy. It cited three main reasons for the latest move. Dilution of the 2.5 million shares sold through ATM The slightly higher operating expenses...

H.C. Wainwright’s Andrew S. Fein believes the bull thesis for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) can no longer by supported only by Orkambi, and the company needs to focus on developing and diversifying its pipeline. Fein reiterated a Buy rating on the company, with a $155...

Viking Therapeutics Inc (NASDAQ: VKTX) is up 87 percent on Thursday, trading at $2.66. The clinical-stage biopharmaceutical company was incorporated in 2012, and went public in 2015. At just shy of a year old, the metabolic/endocrine solutions company has seen some challenges, and is down 70...

HC Wainwright unit Rodman & Renshaw’s Raghuram Selvaraju, maintained a Buy rating for Valeant Pharmaceuticals Intl Inc (NYSE: VRX), while reducing the price target from $150 to $118, after the company lowered its guidance for 2016. Management reduced its 2016 revenue guidance from $12...

Despite having recovered some of the losses over the last three months, Relypsa Inc (NASDAQ: RLYP) shares are down 8 percent year-to-date. H.C. Wainwright’s Ed Arce initiated coverage of the company with a Buy rating and a price target of $63. Arce believes that Veltassa is well...

In a report published Tuesday, H.C. Wainwright analyst Ed Arce initiated coverage of CymaBay Therapeutics Inc (NASDAQ: CBAY) with a Buy rating and $12.00 price target. The note looks into several aspects of the company; so, let’s take a look at some highlights. The firm believes that...

In a report published Thursday, H.C. Wainwright analyst Amit Dayal assumed coverage of Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) with a Buy rating and a price target of $2.50. Ballard Power, a manufacturer of fuel cell products based on Proton Exchange Membrane or PEM fuel cell technology...

H.C. Wainwright downgraded Marchex, Inc. (NASDAQ: MCHX) from Overweight to Equal-weight. Marchex shares have dropped 59.02 percent over the past 52 weeks, while the S&P 500 index has surged 4.48 percent in the same period. Marchex shares closed at $4.95 in pre-market trading.

H.C. Wainwright initiated coverage on Heat Biologics Inc (NASDAQ: HTBX) with a Buy rating. The target price for Heat Biologics is set to $13. Heat Biologics shares have gained 41.32 percent over the past 52 weeks, while the S&P 500 index has surged 11.87 percent in the same period. Heat...

H.C. Wainwright commented on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Wednesday following the FDA AdCom endorsement to approve Orkambi as the stock surged over 5 percent in pre-market trading. Analyst Andrew S. Fein believed that since the Phase 3 win and going into the AdCom, “...

In a report published Monday, H.C. Wainwright analysts initiated coverage of Stemline Therapeutics Inc (NASDAQ: STML) with a Buy rating and a price target of $38. Stemline Therapeutics is an emerging player in the biotechnology filed and is focusing on the development of novel anti-cancer...